ArticleIranian journal of biotechnology2026
Site-Specific PEGylation at Residue 86 Improves Pharmacokinetic Properties of Interferon α-2b.
Article in Iranian journal of biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interferon alpha-2b, a therapeutic protein, suffers from short half-life. PEGylation extends its circulation time but reduces activity. Site-specific PEGylation on cysteine residues, offers a strategy for improved conjugates. Objectives: This study explores cysteine analogs of interferon for site-specific PEGylation and assesses their pharmacokinetic properties. Materials and Methods: Surface-exposed amino acids, identified through in silico studies, were selected for cysteine substitution based on the spatial accessibility of the introduced cysteine for site-specific PEGylation. The resulting mutant genes were synthesized, cloned into the pET26-b vector, and expressed in E. coli. The recombinant proteins were purified by immobilized metal chelate affinity chromatography (IMAC) and their biological activity was assessed via cell-based assays. PEGylation was performed using a 5 kDa Methoxy PEG Maleimide, and the resulting conjugate was purified by ion-exchange chromatography. The pharmacokinetic properties of both the PEGylated and unmodified interferon were then evaluated in rat blood circulation. Results: The in-silico modeling of interferon α-2b identified surface-exposed residues Glu78 and Thr86 as candidates for cysteine substitution. Successful gene synthesis and cloning in Conclusion: PEGylation at position 86 improves early interferon pharmacokinetic properties, but longer-term stability requires investigation of higher molecular weight or branched PEG. These findings underline the importance of strategic amino acid modifications and PEGylation in optimizing therapeutic proteins for improved efficacy and stability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.